Inoviq Ltd
IIQ
Company Profile
Business description
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.
Contact
23 Normanby Road
Notting Hill
MelbourneVIC3168
AUST: +61 395487586
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
stocks
Tesla: Trump election may solidify near-term Tesla US EV leadership
Do possible benefits from the election make shares attractive?
stocks
ASX players that might thrive under a Trump administration
Recent election results have sent US markets into a record-high rally however implications remain mixed for the Australian share market. See our top ASX picks that could do better under a second Trump administration.
stocks
3 "buy the dip" candidates with wide moats
Share price pullbacks can present an opportunity to buy high quality companies at attractive prices.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,479.90 | 29.00 | 0.34% |
| CAC 40 | 7,310.82 | 93.99 | 1.30% |
| DAX 40 | 19,288.07 | 284.96 | 1.50% |
| Dow JONES (US) | 43,958.19 | 47.21 | 0.11% |
| FTSE 100 | 8,077.33 | 47.00 | 0.59% |
| HKSE | 19,435.81 | 387.64 | -1.96% |
| NASDAQ | 19,230.72 | 50.68 | -0.26% |
| Nikkei 225 | 38,535.70 | 185.96 | -0.48% |
| NZX 50 Index | 12,692.94 | 18.45 | 0.15% |
| S&P 500 | 5,985.38 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,224.00 | 30.60 | 0.37% |
| SSE Composite Index | 3,379.84 | 59.44 | -1.73% |